Lutronic Launches SPECTRA XT

Aesthetic and medical device company Lutronic has launched the SPECTRA XT, a multiplatform Nd:YAG laser with features including a 10mm spot size; numerous handpieces; and 1064nm, 532nm, 595nm and 660nm wavelengths. In addition to its long list of indications, including melasma and vascular lesions, the SPECTRA XT recently updated its CE Mark to include three new indications: erythema, traumatic tattoo...

Articles

Lutronic Launches SPECTRA XT

Aesthetic and medical device company Lutronic has launched the SPECTRA XT, a...

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the U.S. Food and...

Galderma Launches SKINPACT Awards

Galderma, in partnership with the International League of Dermatologic Societies (ILDS...

In a study published in Dermatologic Surgery (September 2014), researchers...

Products

On-the-Go Skin Care

Avène offers the limited-edition Revitalizing Hydration Kit just in time for...

Multi-Laser Hair Removal

The Soprano ICE Multi Package from Alma Lasers uses multiple lasers and...

Skin Lightening Complex

Skinprint’s Recover Lightening Complex features BioJuv DS and hydroquinone...

Next Level Microneedling

The Eclipse MicroPen Elite features a stronger motor, longer battery life...

Lutronic Launches SPECTRA XT

Aesthetic and medical device company Lutronic has launched the SPECTRA XT, a multiplatform Nd:YAG laser with features including a 10mm spot size; numerous handpieces; and 1064nm, 532nm, 595nm and 660nm wavelengths. In addition to its long list of indications, including melasma and vascular lesions, the SPECTRA XT recently updated its CE Mark to include three new indications: erythema, traumatic tattoo and acne.

Lutronic presented the laser at the 23rd European Academy of Dermatology and Venereology (EADV) Congress. “We are excited to see the SPECTRA XT was well received by European physicians at the EADV,” said Haelyung Hwang, CEO of Lutronic, South Korea. “Lutronic is focused on developing highly efficacious systems that are versatile—this latest clearance furthers this effort.”

For more information, visit www.lutronic.com.

Image copyright Getty Images

ISHRS Announces 2014 Award Recipients

The International Society of Hair Restoration Surgery (ISHRS) presented awards for service and dedication at its 22nd Annual Scientific Meeting earlier in October.

Russell G. Knudsen, MBBS, FISHRS, of Sydney, Australia, received the 2014 Manfred Lucas Award for demonstrated excellence in hair restoration and long-standing dedication to the highest ISHRS ethical standards. Dr. Knudsen is past president of the ISHRS and has written two textbooks on hair transplantation.

The Golden Follicle Award was presented to James A. Harris, MD, FISHRS, of Denver, Colorado, for his significant clinical contributions to hair restoration surgery. Dr. Harris was an early pioneer of follicular unit extraction and serves on the ISHRS Bard of Governors.

Kenneth J. Washenik, MD, PhD, FISHRS, of Beverly Hills, California, received the Platinum Follicle Award for his research on cellular-based hair restoration and tissue-engineered hair follicle neogenesis. Dr. Washenik is the CEO of the Adderans Research Institute concentrating on hair follicle cloning.

The 2014 Distinguished Assistant Award was presented to Laureen Gorham, RN, from Dorchester, Massassachusetts, for her service and accomplishments as a hair...

FDA Advisory Committee Recommends Approval of AIN457 (Secukinumab) for Psoriasis

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the U.S. Food and Drug Administration (FDA) supported the approval of Novartis Pharmaceuticals’ AIN457 (secukinumab)—a selective interleukin-17A (IL-17A) inhibitor indicated for the treatment of plaque psoriasis—in a unanimous vote. The recommendation was based on results from 10 Phase 2 and Phase 3 clinical trials that evaluated the safety and efficacy of secukinumab in nearly 4,000 patients with moderate to severe psoriasis.

In the Phase 3 trials, secukinumab met all primary endpoints and key secondary endpoints. It demonstrated significant skin clearance at Week 12, and a majority of the patients maintained results at Week 52 with continued treatment. The incidence of serious adverse events was low and comparable for the secukinumab and placebo; common adverse events reported in the treatment group were nasopharyngitis, headache, diarrhea, itching and upper respiratory infection.

FDA action on the Biologics License Application (BLA) is expected in early 2015.